EP1070122A4 - Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale - Google Patents

Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale

Info

Publication number
EP1070122A4
EP1070122A4 EP99913854A EP99913854A EP1070122A4 EP 1070122 A4 EP1070122 A4 EP 1070122A4 EP 99913854 A EP99913854 A EP 99913854A EP 99913854 A EP99913854 A EP 99913854A EP 1070122 A4 EP1070122 A4 EP 1070122A4
Authority
EP
European Patent Office
Prior art keywords
apoptic
induction
codelivery
cytotoxic
gene expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99913854A
Other languages
German (de)
English (en)
Other versions
EP1070122A2 (fr
Inventor
Timothy J Mcdonnell
Stephen G Swisher
Bingliang Fang
Elizabeth M Bruckheimer
Mona G Sarkiss
Li Ji
Jack A Roth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of EP1070122A2 publication Critical patent/EP1070122A2/fr
Publication of EP1070122A4 publication Critical patent/EP1070122A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne, de manière générale, des vecteurs viraux et leur utilisation comme vecteurs d'expression pour transformer des cellules humaines, in vitro et in vivo. En particulier, la présente invention concerne des vecteurs adénoviraux contenant des gènes propapoptotiques et leur utilisation dans les thérapies anticancéreuses.
EP99913854A 1998-03-11 1999-03-11 Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale Withdrawn EP1070122A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7754198P 1998-03-11 1998-03-11
US77541P 1998-03-11
PCT/US1999/005359 WO1999046371A2 (fr) 1998-03-11 1999-03-11 Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale

Publications (2)

Publication Number Publication Date
EP1070122A2 EP1070122A2 (fr) 2001-01-24
EP1070122A4 true EP1070122A4 (fr) 2004-11-10

Family

ID=22138678

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99913854A Withdrawn EP1070122A4 (fr) 1998-03-11 1999-03-11 Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale

Country Status (4)

Country Link
EP (1) EP1070122A4 (fr)
AU (1) AU762493B2 (fr)
CA (1) CA2322663A1 (fr)
WO (1) WO1999046371A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4764801A (en) * 2000-03-24 2001-10-08 Calydon Inc Cell-specific adenovirus vectors comprising an internal ribosome entry site
ATE444372T1 (de) 2000-05-31 2009-10-15 Human Gene Therapy Res Inst Methode und zusammensetzungen für effizienten gentransfer durch transcomplementierende vektoren
WO2001093899A1 (fr) * 2000-06-02 2001-12-13 Hiroshi Okamoto Promoteur de la proliferation des cellules de langerhans ? pancreatiques et inhibiteur d'apoptose, ainsi que criblage de composes candidats pour ces medicaments
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
EP1207205A1 (fr) * 2000-11-20 2002-05-22 Crucell Holland B.V. Réplicons adénoviraux
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
CA2471719A1 (fr) * 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Methode de traitement de l'apoptose et compositions associees
JP4511108B2 (ja) 2002-05-31 2010-07-28 オンコリクス インコーポレイテッド ヒトプロラクチン拮抗剤−血管新生阻害剤融合蛋白質
CN100361710C (zh) 2004-06-07 2008-01-16 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
US20080081354A1 (en) * 2006-10-02 2008-04-03 Cardiac Pacemakers, Inc. Devices, vectors and methods for inducible ischemia cardioprotection
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
MA52487A (fr) 2018-05-01 2021-03-10 Amgen Inc Pyrimidinones substituées en tant qu'agonistes du récepteur apj
CN110174456B (zh) * 2019-06-11 2021-09-21 华润双鹤药业股份有限公司 一种测定肺表面活性物质蛋白的方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025507A2 (fr) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines
WO1997040180A1 (fr) * 1996-04-20 1997-10-30 Boehringer Ingelheim International Gmbh Virus celo
WO2000015648A1 (fr) * 1998-09-10 2000-03-23 The Uab Research Foundation Vecteur adenoviral codant pour le gene bax pro-apoptotique et utilisations d'un tel vecteur

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025507A2 (fr) * 1995-02-17 1996-08-22 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Procedes de preparation et d'utilisation de vecteurs adenoviraux recombines
WO1997040180A1 (fr) * 1996-04-20 1997-10-30 Boehringer Ingelheim International Gmbh Virus celo
WO2000015648A1 (fr) * 1998-09-10 2000-03-23 The Uab Research Foundation Vecteur adenoviral codant pour le gene bax pro-apoptotique et utilisations d'un tel vecteur

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"RETROVIRAL BAX GENE TRANSFER FAILS TO SENSITIZE MALIGNANT GLIOMA CELLS TO CD95L-INDUCED APOPTOSIS AND CANCER CHEMOTHERAPY", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 77, August 1998 (1998-08-01), pages 645 - 648, XP002922344, ISSN: 0020-7136 *
BOISE L H ET AL: "BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL DEATH", CELL, CELL PRESS, CAMBRIDGE, NA, US, vol. 74, 27 August 1993 (1993-08-27), pages 597 - 608, XP002018919, ISSN: 0092-8674 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, SIMONIAN PHILIP L ET AL: "Bax homodimerization is not required for bax to accelerate chemotherapy-induced cell death", XP002282530, Database accession no. PREV199799338036 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1996, ZHA HONGBIN ET AL: "Proapoptotic protein bax heterodimerizes with Bcl-2 and homodimerizes with bax via a novel domain (BH3) distinct from BH1 and BH2", XP002282529, Database accession no. PREV199698772776 *
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; December 1993 (1993-12-01), KORSMEYER S J ET AL: "Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death.", XP002282531, Database accession no. NLM8142617 *
DERROW S ET AL: "Apoptosis induction by adenovirus-bclx-s: A rational strategy for bladder cancer gene therapy", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 38, no. 0, 1997, & EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN DIEGO, CALIFORNIA, USA; APRIL 12-16, 1997, pages 11, XP002282532, ISSN: 0197-016X *
DERROW SOL ET AL: "Apoptosis induction by adenovirus-BCLX-S: A rational strategy for bladder cancer gene therapy", JOURNAL OF UROLOGY, vol. 157, no. 4 SUPPL., 1997, & 92ND ANNUAL MEETING OF THE AMERICAN UROLOGICAL ASSOCIATION; NEW ORLEANS, LOUISIANA, USA; APRIL 12-17, 1997, pages 310, XP008031086, ISSN: 0022-5347 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 13, 1996, pages 7440 - 7444, ISSN: 0021-9258 *
JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 50, 1996, pages 32073 - 32077, ISSN: 0021-9258 *
KAGAWA S ET AL: "Induction of bax gene expression by adenoviral mediated gene codelivery", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03-01), & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999, pages 218, XP002282528, ISSN: 0197-016X *
See also references of WO9946371A3 *
SEMINARS IN CANCER BIOLOGY. DEC 1993, vol. 4, no. 6, December 1993 (1993-12-01), pages 327 - 332, ISSN: 1044-579X *

Also Published As

Publication number Publication date
WO1999046371A3 (fr) 2000-08-24
EP1070122A2 (fr) 2001-01-24
WO1999046371A2 (fr) 1999-09-16
WO1999046371A9 (fr) 2000-02-17
CA2322663A1 (fr) 1999-09-16
AU762493B2 (en) 2003-06-26
AU3183799A (en) 1999-09-27

Similar Documents

Publication Publication Date Title
EP1070122A4 (fr) Induction de l'expression de genes apoptotiques ou cytotoxiques par co-apport de genes a mediation adenovirale
EP1017797A4 (fr) Vecteurs de lentivirus non originaires de primates et systemes d'encapsidation
EP1315512A4 (fr) Ciblage ad noviral et manipulation de la r ponse du syst me immunitaire au moyen de peptides ciblants
IL159637A0 (en) Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
PL339735A1 (en) Pappiloma virus capsomer vaccine compositions and methods of applying them
WO2001022990A3 (fr) Methodes concernant l'interferon induit par acides nucleiques immunostimulateur
HUP9902310A2 (hu) Komplementer adenovírus-vektorrendszerek és sejtvonalak
WO2000054813A3 (fr) Utilisation de vecteurs d'administration d'un gene recombinant pour le traitement ou la prévention des maladies de l'oeil
WO2000073478A3 (fr) Vecteurs adenoviraux recombinants pour l'infection specifique de cellules, l'integration de genomes et l'expression de proteines fibreuses chimeriques
WO2003023000A3 (fr) Fragments d'adn lineaires destines a l'expression genetique
IL146125A0 (en) Novel quinones as disease therapies
WO2001077080A3 (fr) Composes de pyrazole
AU2002251366A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
WO1999033998A3 (fr) Sequences d'adn regulatrices du gene de la sous-unite telomerase catalytique humaine et leur utilisation a des fins diagnostiques et therapeutiques
WO1999064594A8 (fr) Genes et produits d'expression genique regules de façon differentielle lors du cancer de la prostate
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
DK0843731T3 (da) Adenovirusvektorer til genterapi
AU2164197A (en) Recombinant adenoviral vectors for human tumour gene therapy
AU3209300A (en) Combination therapy of cancer by the activation of co-stimulatory molecules expressed by immune cells and cytokines
ZA200202413B (en) Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression.
WO2001005435A3 (fr) Therapie antisens pour tumeurs a regulation hormonale
AU7794700A (en) Recombinant adenoviruses preparation and adenovirus banks
EP1390388A4 (fr) Modulation antisens de l'expression du recepteur 1 de l'interferon gamma
WO2000006735A8 (fr) HYBRIDES D'INTERFERON-$g(a)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001011

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 35/00 B

Ipc: 7A 61K 48/00 B

Ipc: 7C 12N 15/86 B

Ipc: 7A 01N 43/04 B

Ipc: 7C 12N 15/00 A

A4 Supplementary search report drawn up and despatched

Effective date: 20040922

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROTH, JACK, A.

Inventor name: JI, LI

Inventor name: SARKISS, MONA, G.

Inventor name: BRUCKHEIMER, ELIZABETH, M.

Inventor name: FANG, BINGLIANG

Inventor name: SWISHER, STEPHEN, G.

Inventor name: MCDONNELL, TIMOTHY, J.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROTH, JACK, A.

Inventor name: JI, LI

Inventor name: SARKISS, MONA, G.

Inventor name: BRUCKHEIMER, ELIZABETH, M.

Inventor name: FANG, BINGLIANG

Inventor name: SWISHER, STEPHEN, G.

Inventor name: MCDONNELL, TIMOTHY, J.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20070515BHEP

Ipc: A61K 48/00 20060101ALI20070515BHEP

Ipc: C12N 15/861 20060101ALI20070515BHEP

Ipc: C12N 15/86 20060101ALI20070515BHEP

Ipc: A01N 43/04 20060101ALI20070515BHEP

Ipc: C12N 15/00 20060101AFI20070515BHEP

RTI1 Title (correction)

Free format text: ADENOVIRUS FOR THE INDUCTION OF APOPTIC GENE EXPRESSION

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ROTH, JACK, A.

Inventor name: JI, LI

Inventor name: SARKISS, MONA, G.

Inventor name: BRUCKHEIMER, ELIZABETH, M.

Inventor name: FANG, BINGLIANG

Inventor name: SWISHER, STEPHEN, G.

Inventor name: MCDONNELL, TIMOTHY, J.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081001